Skip to main content

Table 3 Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-A*2402-matched patients)

From: Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Variables The number of peptide specific response p-value
0 or 1 2 or 3
the number of patients 10 26  
Age 69.3 ± 3.7 60.5 ± 2.4 0.1075
Gender    0.4629
 Male 6 11  
 Female 4 15  
Stage (UICC)    0.5209
 III 2 5  
 IV 8 18  
 Recurrence 0 3  
NLR 3.61 ± 0.32 2.14 ± 0.16 0.0007
CRP 1.39 ± 0.48 0.58 ± 0.17 0.1425
IL-6 2.11 ± 0.70 19.40 ± 17.32 0.7640
PD-1+ CD4+ T cell 3.46 ± 0.56 1.58 ± 0.17 0.0007
Tim-3+ CD4+ T cell 3.30 ± 0.53 3.71 ± 0.68 0.8184
PD-1+ CD8+ T cell 5.63 ± 0.74 4.05 ± 0.45 0.0689
Tim-3+ CD8+ T cell 5.37 ± 0.98 4.77 ± 0.49 0.7108
Treg 2.41 ± 0.28 1.64 ± 0.13 0.0121
MDSC 17.34 ± 1.70 14.29 ± 0.78 0.1005
  1. Statistical significant results are highlighted in bold letters
  2. Abbreviations: HLA human leukocyte antigen, CI confidence interval, UICC Union for International Cancer, NLR neutrophil lymphocyte ration, CRP C-reactive protein, IL-6 interleukin-6, PD-1 Programmed death-1, Tim-3 T cell immunoglobulin mucin-3, Treg Regulatory T cell, MDSC Myeloid-derived suppressor cell